Shared genetic architecture ties psoriasis to cardiovascular risk
Psoriasis and cardiovascular disease have long coexisted at the bedside, with inflammation as the obvious clinical bridge and heredity as the less visible one. This preprint pushes the question deeper into the genome. By integrating large-scale European-ancestry genome-wide summary statistics for psoriasis and seven cardiovascular diseases, investigators mapped a measurable pattern of shared liability rather than a vague epidemiologic association.
The central finding is straightforward and clinically relevant: psoriasis showed modest genetic correlations with all cardiovascular outcomes examined, yet mixture modeling suggested that more than half of psoriasis-associated non-zero variants were shared with five cardiovascular diseases. In other words, the overlap is not confined to a handful of common inflammatory markers. It appears to extend across a broader liability structure that could help explain why patients with psoriasis experience higher cardiovascular morbidity than skin disease alone would predict.
Latent liability exposed loci missed by single-trait analysis
One of the most interesting signals came from genomic structural equation modeling of a latent psoriasis-cardiovascular disease factor. That analysis identified 167 independent risk loci, including 50 loci that did not reach genome-wide significance in any single component trait. The result matters because single-disease genetic scans can miss pleiotropic variants that exert modest effects across more than one disorder. When the biology is shared, the statistical signal strengthens only when the phenotypes are modeled together.
This kind of architecture fits the clinical phenotype. Psoriasis is not simply a skin-limited process; it is an immune-mediated systemic disease in which chronic inflammation, endothelial stress, and metabolic dysfunction can converge. A latent factor that captures both dermatologic and cardiovascular risk offers a more plausible map of the underlying biology than isolated trait-by-trait comparisons. It also suggests why some patients carry a heavier cardiovascular burden even when traditional risk assessment appears incomplete.
Candidate genes point toward inflammatory and metabolic pathways
Multimodal prioritization nominated 473 candidate genes and 90 approved compounds with therapeutic relevance. Among the shared targets were PDE4B, GLP1R, KEAP1 and PRDM16. Each of these genes points to a different layer of biology: immune signaling, metabolic regulation, oxidative stress responses, and energy homeostasis. The convergence is striking because it moves the discussion beyond a single mechanism such as inflammation alone.
PDE4B is especially familiar in psoriasis biology because phosphodiesterase signaling influences inflammatory cell activity. GLP1R implicates cardiometabolic pathways that may matter in patients whose cardiovascular risk is amplified by obesity, dysglycemia, or related traits. KEAP1 connects to oxidative stress defenses, a relevant axis in vascular injury and plaque biology. PRDM16 adds another layer, suggesting that tissue-level energy regulation may intersect with systemic risk in ways that are still being defined.
The list of 90 approved compounds is more than a catalog of repurposing candidates. It reflects the possibility that a subset of therapies developed for one disease domain could be biologically relevant to the other, at least in principle. The study does not establish clinical efficacy for any specific drug in psoriasis-associated cardiovascular risk, but it does provide a rational shortlist for mechanistic and translational follow-up.
Cardiometabolic traits explain part, but not most, of the overlap
Mediation and Mendelian randomization analyses implicated cardiometabolic traits in the shared genetic liability. Even so, no single trait accounted for more than half of the overlap. That finding is important because it resists the temptation to reduce the psoriasis-cardiovascular connection to obesity, diabetes, or lipid biology alone. Those traits matter, but they do not absorb the full signal.
At the bedside, this supports a broader model of risk. A patient with psoriasis may accumulate cardiovascular vulnerability through several partially overlapping routes: systemic inflammation, metabolic disturbance, endothelial dysfunction, and genetic predisposition that cuts across organ systems. The study’s results align with that layered reality. They also help explain why cardiovascular prevention in psoriasis cannot rely on one biomarker or one explanatory pathway.
What the analysis can and cannot claim
The work is powerful in scope, but it remains a genetic analysis built on summary statistics rather than an interventional trial or prospective clinical cohort. It establishes shared architecture, not causation in the therapeutic sense. It also focuses on European-ancestry data, which limits how broadly the findings can be generalized without additional work in more diverse populations.
Still, the study has a practical value that goes beyond statistical elegance. It identifies loci that single-trait studies may miss, prioritizes candidate genes for functional work, and points to compounds that deserve biological scrutiny. For clinicians, the takeaway is not that psoriasis should be treated as cardiovascular disease. It is that the two conditions may share a deeper inherited scaffold than routine risk factor management alone can capture.
Future work will need to determine which of these shared loci are driving vascular events, which are merely markers of correlated biology, and whether any of the nominated targets can be leveraged to lower cardiovascular risk in patients with psoriasis. Until then, the preprint offers a dense genetic map of a clinical association that has been visible for years but only partially explained.